STOCK TITAN

IRulya Therapeutics grants director 17,000-share option

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

IRulya Therapeutics Inc. director John Drayton Wise received a director stock option covering 17,000 shares of common stock on November 9, 2026, with an exercise price of $33.78 per share. The option vests in 36 successive equal monthly installments beginning October 8, 2026, subject to his continued service with the company on each vesting date. His reported post-transaction position is an option covering 17,000 common shares.

Insider Wise John Drayton
Role Director
Type Security Shares Price Value
Grant/Award Director Stock Option (Right to Buy) F1 17,000 $0.00 $0.00
Holdings After Transaction: Director Stock Option (Right to Buy) — 17,000 options (Direct)
Holdings Before and After: Director Stock Option (Right to Buy), 0 to 17,000 options (Direct)
Footnotes (1)
  1. F1. Beginning October 8, 2026, the shares subject to the option vest in a series of thirty-six (36) successive equal monthly installments, subject to the Reporting Person's Continued Service (as defined in the Issuer's 2026 Equity Incentive Plan) with the Issuer as of each such vesting date.
Option shares 17,000 shares Director stock option granted November 9, 2026
Exercise price $33.78 per share Director stock option
Vesting installments 36 monthly installments Beginning October 8, 2026, subject to continued service
Director Stock Option (Right to Buy) technical
"Director Stock Option (Right to Buy)"
Continued Service technical
"subject to the Reporting Person's Continued Service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did IRLA director John Drayton Wise receive in his option award?

John Drayton Wise received an option covering 17,000 shares of common stock, with an exercise price of $33.78 per share. It vests in 36 successive equal monthly installments beginning October 8, 2026, subject to his continued service on each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Wise John Drayton

(Last)(First)(Middle)
C/O IRULYA THERAPEUTICS INC.
101 COLLEGE STREET, SUITE 210

(Street)
NEW HAVEN CONNECTICUT 06510

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
IRulya Therapeutics Inc. [ IRLA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/09/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Director Stock Option (Right to Buy)$33.7811/09/2026A17,000 (1) (1)Common Stock17,000$017,000D
Explanation of Responses:
1. Beginning October 8, 2026, the shares subject to the option vest in a series of thirty-six (36) successive equal monthly installments, subject to the Reporting Person's Continued Service (as defined in the Issuer's 2026 Equity Incentive Plan) with the Issuer as of each such vesting date.
/s/ John Militello, Attorney-in-Fact11/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading